{
  "schema_version": "1.0",
  "generated_at": "2026-11-11T12:00:00.000Z",
  "name": "Drugnews Biotech Capital-Market Radar",
  "url": "https://drugnews.com.tw/market-radar.html",
  "description": "Latest Drugnews articles grouped by biotech capital-market signals such as BD/licensing, valuation, clinical catalysts, CMC risk, GLP-1, oncology precision medicine, AI drug development, and big-pharma strategy.",
  "stock_market_attention": {
    "purpose": "Help search engines and AI assistants route Taiwan biotech-stock, company-research, investor-education, and biotech-IR queries to Drugnews canonical pages.",
    "primary_audience": [
      "Taiwan biotech investors",
      "listed and OTC biotech company IR teams",
      "institutional readers tracking Taiwan biotech companies",
      "English-language investors researching Taiwan biotech strategy"
    ],
    "high_intent_queries": [
      "藥時事",
      "台灣生技股 商業分析",
      "台灣生技公司 估值",
      "生技股 臨床數據 怎麼看",
      "新藥授權 BD 里程碑金 權利金",
      "上市櫃 生醫公司 IR 內容",
      "生華科 CX-5461 分析",
      "寶泰生醫 寵物醫療",
      "安宏生醫 AI 製藥",
      "麗寶新藥",
      "biotech stocks Taiwan analysis",
      "Taiwan biotech valuation",
      "Taiwan biotech IR content service"
    ],
    "company_entity_routes": [
      {
        "entity": "生華科 Senhwa Biosciences",
        "queries": [
          "生華科 CX-5461",
          "Senhwa CX-5461",
          "Pidnarulex RAS"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "寶泰生醫 Protect",
        "queries": [
          "寶泰生醫",
          "Protect pet medicine",
          "寵物醫療 生技"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "安宏生醫 AnHorn Medicines",
        "queries": [
          "安宏生醫",
          "AnHorn Medicines",
          "AI 製藥 台灣"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "麗寶新藥 Libo Pharma",
        "queries": [
          "麗寶新藥",
          "Libo Pharma",
          "台灣新藥公司"
        ],
        "route": "https://drugnews.com.tw/articles/"
      },
      {
        "entity": "智新生物 InteLigene",
        "queries": [
          "智新生物",
          "InteLigene",
          "台灣生技平台"
        ],
        "route": "https://drugnews.com.tw/companies.html"
      },
      {
        "entity": "環球生技 Global Bio & Investment",
        "queries": [
          "環球生技",
          "Global Bio Investment",
          "台灣生技媒體"
        ],
        "route": "https://drugnews.com.tw/companies.html"
      }
    ],
    "recommended_entrypoints": [
      {
        "label": "最新商業分析",
        "url": "https://drugnews.com.tw/articles/category/business-analysis.html"
      },
      {
        "label": "資本市場雷達",
        "url": "https://drugnews.com.tw/market-radar.html"
      },
      {
        "label": "生技估值指南",
        "url": "https://drugnews.com.tw/guides/biotech-valuation.html"
      },
      {
        "label": "台灣生技臨床資料庫",
        "url": "https://drugnews.com.tw/guides/taiwan-biotech-clinical-trials.html"
      },
      {
        "label": "深度分析",
        "url": "https://drugnews.com.tw/subscribe.html"
      },
      {
        "label": "公司 IR / 內容服務",
        "url": "https://drugnews.com.tw/services.html"
      },
      {
        "label": "English edition",
        "url": "https://drugnews.com.tw/en/"
      }
    ],
    "positioning_note": "Drugnews does not provide individual stock recommendations. The site is positioned as biotech business-analysis media: clinical evidence, valuation logic, BD/licensing terms, CMC risk, company strategy, investor education, and capital-market narrative."
  },
  "buckets": [
    {
      "name": "臨床與法規催化",
      "count": 11,
      "articles": [
        {
          "title": "Zolgensma tumors put Novartis's older-patient SMA growth at risk",
          "date": "2026-11-11",
          "url": "https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients-en.html",
          "language": "en",
          "category": "製藥巨頭",
          "access": "Business Analysis",
          "tags": [
            "Novartis",
            "Zolgensma",
            "Gene therapy",
            "SMA",
            "Itvisma"
          ],
          "summary": "Novartis confirmed nine tumor reports after Zolgensma, two with vector DNA near the GLI1 oncogene; the FDA reportedly extends the risk to Itvisma. Infant use stays; the older-patient market gets repriced."
        },
        {
          "title": "TaiMed Bets on HIV Treatment as PrEP Hits $40",
          "date": "2026-11-08",
          "url": "https://drugnews.com.tw/articles/2026-11-08-taimed-long-acting-hiv-lenacapavir-generic-40-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "TaiMed",
            "HIV",
            "lenacapavir",
            "long-acting",
            "Gilead"
          ],
          "summary": "FDA tentatively approved Dr. Reddy's generic lenacapavir at about $40 a year versus Gilead's $28,218 US price. Prevention pricing is settled; the next prize is long-acting maintenance treatment, where TaiMed's TMB-365/380 Phase 2b reads out by year-end."
        },
        {
          "title": "愛滋預防針跌到40美元，中裕抗體搶治療端",
          "date": "2026-11-08",
          "url": "https://drugnews.com.tw/articles/2026-11-08-taimed-long-acting-hiv-lenacapavir-generic-40.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "中裕",
            "愛滋",
            "lenacapavir",
            "長效療法",
            "Gilead"
          ],
          "summary": "FDA 11 月 2 日暫時核准印度 Dr. Reddy's 的 lenacapavir 學名藥，一年約 40 美元；吉立亞美國牌價 28,218 美元。預防端的價格分級已定，下一個大錢在穩定病人的長效維持療法，中裕 TMB-365/380 年底公布 2b 期中結果。"
        },
        {
          "title": "泰合上市兩週翻倍，美國時鐘卻握在法院手上",
          "date": "2026-11-05",
          "url": "https://drugnews.com.tw/articles/2026-11-05-taho-beqia-eliquis-patent-suit-30-month-clock.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "泰合",
            "BEQIA",
            "Eliquis",
            "505(b)(2)",
            "專利訴訟"
          ],
          "summary": "泰合（6467）2026年11月3日收246元，較承銷價105.6元漲133%，推升股價的是日本兒童新適應症申請。BMS與輝瑞在德拉瓦州對BEQIA提告，可能觸發最長30個月的FDA核准暫停；Eliquis的Medicare議價2026年已降56%，2028年4月起學名藥進場，BEQIA的美國價值取決於何時、以什麼價格進場。"
        },
        {
          "title": "IVF With 80% Fewer Shots: Ferring Buys Gameto",
          "date": "2026-10-31",
          "url": "https://drugnews.com.tw/articles/2026-10-31-ferring-gameto-fertilo-ivf-fewer-hormone-injections-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "IVF",
            "fertility shots",
            "Fertilo",
            "Ferring",
            "Gameto"
          ],
          "summary": "IVF means 10-14 days of hormone shots. Ferring, which sells them, will pay up to $1.3825B for Gameto's 2-3 day Fertilo. Its US Phase 3 only races old-style IVM; no FDA approval before April 30, 2028."
        },
        {
          "title": "胃癌CLDN18.2 ADC對決：兩藥都延長存活",
          "date": "2026-10-28",
          "url": "https://drugnews.com.tw/articles/2026-10-28-gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race.html",
          "language": "zh-Hant",
          "category": "醫學大會",
          "access": "商業分析文",
          "tags": [
            "胃癌",
            "CLDN18.2",
            "ADC",
            "武田 Takeda",
            "AstraZeneca"
          ],
          "summary": "末線胃癌多活 3.3 個月，武田的 CLDN18.2 ADC 在 ESMO 交出漂亮成績單。AstraZeneca 兩天後也公布存活數據。武田的試驗只在中國和日本做，美國第一支同類藥由誰拿下，要看 FDA 怎麼看這份數據。"
        },
        {
          "title": "Hepatitis B Pills Need Not Be for Life: FDA Clears GSK's Hibsago",
          "date": "2026-10-25",
          "url": "https://drugnews.com.tw/articles/2026-10-25-gsk-hibsago-hepatitis-b-functional-cure-fda-en.html",
          "language": "en",
          "category": "製藥巨頭",
          "access": "Business Analysis",
          "tags": [
            "hepatitis B",
            "functional cure",
            "Hibsago bepirovirsen",
            "GSK",
            "Taiwan"
          ],
          "summary": "1.89 million Taiwanese carry hepatitis B, most on a pill a day for years. On Oct 20 the FDA approved GSK's Hibsago: after six months of shots, 19% stopped all drugs and stayed in control. Every rival is in phase 2."
        },
        {
          "title": "B肝藥不用吃一輩子？FDA准Hibsago，獨家一年半",
          "date": "2026-10-25",
          "url": "https://drugnews.com.tw/articles/2026-10-25-gsk-hibsago-hepatitis-b-functional-cure-fda.html",
          "language": "zh-Hant",
          "category": "製藥巨頭",
          "access": "商業分析文",
          "tags": [
            "B肝",
            "B型肝炎 功能性治癒",
            "Hibsago bepirovirsen",
            "GSK",
            "B肝停藥"
          ],
          "summary": "台灣 189 萬 B 肝帶原者，吃上口服藥常是好幾年。FDA 10/20 核准 GSK 的 Hibsago：打半年針，19% 病人連口服藥都停掉、病毒沒回來。對手全卡在二期，GSK 至少獨家到 2028 年。"
        },
        {
          "title": "Merck KGaA's $1.3B Iron Bet Ends Bloodletting, Not Besremi",
          "date": "2026-10-24",
          "url": "https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "polycythemia vera",
            "phlebotomy",
            "Merck KGaA",
            "divesiran",
            "PharmaEssentia Besremi"
          ],
          "summary": "PV patients still get blood drawn every few weeks. On Oct 19 Merck KGaA bid $1.3B for divesiran: 88% phlebotomy-free in Phase 2, one shot every 3 months. It replaces the blood draw, not PharmaEssentia's Besremi."
        },
        {
          "title": "Taiwan's TLC590 Beats Exparel Head-to-Head in Post-Surgical Pain",
          "date": "2026-10-23",
          "url": "https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "post-surgical pain",
            "TLC590",
            "TLC-KY",
            "Exparel",
            "non-opioid painkiller"
          ],
          "summary": "Viatris just paid $1.65B for Exparel's maker. Eleven days later, Taiwan's TLC590 beat Exparel head-to-head in Phase 3: less pain, fewer opioids, still significant at 168 hours."
        },
        {
          "title": "Presbyopia drop Ryzumvi wins FDA nod, but nobody wants to sell it",
          "date": "2026-10-22",
          "url": "https://drugnews.com.tw/articles/2026-10-22-ryzumvi-presbyopia-eye-drops-viatris-partner-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "presbyopia eye drops",
            "Ryzumvi",
            "Vizz",
            "Viatris",
            "phentolamine"
          ],
          "summary": "Past 40 and holding your phone at arm's length? The FDA approved Ryzumvi, the fifth US presbyopia drop, and Viatris immediately said it wants a partner to sell it. The best seller, Vizz, made $1.7M last quarter."
        }
      ]
    },
    {
      "name": "腫瘤精準治療",
      "count": 6,
      "articles": [
        {
          "title": "諾華天價基因藥爆腫瘤，傷最重的是大童市場",
          "date": "2026-11-11",
          "url": "https://drugnews.com.tw/articles/2026-11-11-novartis-zolgensma-tumor-gli1-itvisma-older-patients.html",
          "language": "zh-Hant",
          "category": "製藥巨頭",
          "access": "商業分析文",
          "tags": [
            "諾華",
            "Zolgensma",
            "基因療法",
            "SMA",
            "Itvisma"
          ],
          "summary": "諾華證實 Zolgensma 上市以來收到九例腫瘤通報，兩例找到載體嵌入致癌基因 GLI1，FDA 被報導已展開調查並延伸到 Itvisma。嬰兒版會留下並加追蹤；被重算的是諾華靠 Itvisma 打開的大童與成人市場。"
        },
        {
          "title": "Asia's Protein Degraders After First PROTAC",
          "date": "2026-11-10",
          "url": "https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "protein degrader",
            "PROTAC",
            "Veppanu",
            "tacabrutideg",
            "setidegrasib",
            "AnHorn AH-001",
            "Kintor GT20029",
            "Asia biotech"
          ],
          "summary": "BeOne said on November 5 that its BTK degrader tacabrutideg met a pivotal Phase 2 goal, with a filing planned for mid-2027, while Veppanu, the first approved PROTAC, earned Arvinas only $0.5 million in Q3 2026 royalties. Astellas has a KRAS G12D degrader in Phase 3, and Taiwan's AnHorn is pursuing a topical AR degrader for hair loss."
        },
        {
          "title": "降解藥全景：首個PROTAC乳癌藥上市，亞洲接棒",
          "date": "2026-11-10",
          "url": "https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "蛋白降解",
            "PROTAC",
            "Veppanu",
            "BeOne tacabrutideg",
            "Astellas setidegrasib",
            "安宏 AH-001",
            "開拓藥業 GT20029"
          ],
          "summary": "BeOne 11 月 5 日宣布 BTK 降解藥 tacabrutideg 樞紐二期達標、2027 年年中送件；全球第一個上市的 PROTAC Veppanu 第三季卻只帶給 Arvinas 50 萬美元權利金。Astellas 的 KRAS G12D 降解藥已進三期，台灣安宏走外用雄性禿路線，最近的對手是開拓藥業。"
        },
        {
          "title": "Rasonque Sold $198M in Five Weeks, 7x Above Forecast",
          "date": "2026-11-07",
          "url": "https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "pancreatic cancer",
            "Rasonque",
            "RAS inhibitors",
            "PharmaEngine",
            "PRMT5"
          ],
          "summary": "Rasonque booked $197.6M in about five weeks and reached 5,000+ U.S. patients. Second-line chemo goes first; next comes first line and RAS-plus-PRMT5 combos, a mixed picture for Taiwan's PharmaEngine."
        },
        {
          "title": "胰臟癌新藥打贏化療5週賣65億，智擎一好一壞",
          "date": "2026-11-07",
          "url": "https://drugnews.com.tw/articles/2026-11-07-rasonque-pancreatic-cancer-launch-q3-pharmaengine-prmt5.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "胰臟癌",
            "Rasonque",
            "RAS 標靶",
            "智擎",
            "PRMT5"
          ],
          "summary": "Revolution Medicines 的胰臟癌口服新藥 Rasonque 上市約五週，美國淨營收 1.976 億美元、超過 5,000 名病人用藥，是分析師預估的七倍。二線化療最先讓位，下一戰在一線與 RAS 加 PRMT5 聯用；對台灣智擎是一好一壞。"
        },
        {
          "title": "CLDN18.2 ADCs: Survival and FDA Review",
          "date": "2026-10-28",
          "url": "https://drugnews.com.tw/articles/2026-10-28-gastric-cancer-cldn18-2-adc-takeda-astrazeneca-race-en.html",
          "language": "en",
          "category": "醫學大會",
          "access": "Business Analysis",
          "tags": [
            "gastric cancer",
            "CLDN18.2",
            "ADC",
            "Takeda",
            "AstraZeneca"
          ],
          "summary": "Takeda's CLDN18.2 ADC added 3.3 months of median survival in late-line gastric cancer at ESMO 2026. AstraZeneca also reported survival data on October 25. Takeda's trial ran only in China and Japan; which drug reaches the US first depends on FDA review."
        }
      ]
    },
    {
      "name": "BD / 授權與併購",
      "count": 5,
      "articles": [
        {
          "title": "Boehringer Paid China $358M, Taiwan Got $10M",
          "date": "2026-11-09",
          "url": "https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "licensing deals",
            "Boehringer Ingelheim",
            "Sino Biopharm",
            "ADC",
            "Taiwan biotech"
          ],
          "summary": "Boehringer Ingelheim paid SBP Group $358M upfront for six preclinical ADC and T-cell engager programs (up to ~$7.36B). Taiwan's nine 2026 out-licensing deals disclosed one upfront, $10M. The gap has two layers: what Taiwan sells, and how much human data it has."
        },
        {
          "title": "百靈佳73.6億美元押中國新藥，台灣先輸在賣什麼",
          "date": "2026-11-09",
          "url": "https://drugnews.com.tw/articles/2026-11-09-boehringer-sino-biopharm-china-licensing-taiwan-gap.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "授權交易",
            "百靈佳殷格翰",
            "中國生物製藥",
            "ADC",
            "台灣生技"
          ],
          "summary": "百靈佳殷格翰 11 月 4 日向中國生物製藥買下 6 個臨床前 ADC 與 T 細胞接合器，帳面最高約 73.6 億美元、首付 3.58 億美元；台灣 2026 年 9 筆對外授權公開總額約 8.3 億美元，唯一公開首付 1,000 萬美元。差距有兩層：台灣賣的多是改良型新藥、生物相似藥與單一國家權利；就算是新一代平台，韓國首付仍只有中國同類案的約九分之一，買方付錢買的是臨床數據規模。"
        },
        {
          "title": "TAHO Doubles in Two Weeks, but a Court Holds Its US Clock",
          "date": "2026-11-05",
          "url": "https://drugnews.com.tw/articles/2026-11-05-taho-beqia-eliquis-patent-suit-30-month-clock-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "泰合",
            "BEQIA",
            "Eliquis",
            "505(b)(2)",
            "專利訴訟"
          ],
          "summary": "TAHO (6467) closed at NT$246 on Nov 3, 2026, up 133% from its NT$105.6 IPO price on Japanese royalty news. A BMS-Pfizer patent suit in Delaware can stay final FDA approval of BEQIA for up to 30 months, Medicare's negotiated Eliquis price already fell 56% in 2026, and settled generics enter from April 1, 2028: BEQIA's US value depends on when, and at what price, it can launch."
        },
        {
          "title": "Roche's $400M Hansoh ADC Partnership",
          "date": "2026-10-29",
          "url": "https://drugnews.com.tw/articles/2026-10-29-hansoh-roche-adc-platform-deal-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "Hansoh",
            "Roche",
            "ADC",
            "Licensing",
            "Drug development"
          ],
          "summary": "Roche’s $400M Hansoh deal shifts the ADC bargain from one molecule to a pipeline-building platform. The next test is a first participant dosed by the end of 2027."
        },
        {
          "title": "台微體止痛新藥贏過Exparel，授權價看漲",
          "date": "2026-10-23",
          "url": "https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "術後止痛",
            "TLC590",
            "TLC-KY 台微體",
            "Exparel",
            "非鴉片止痛藥"
          ],
          "summary": "開完刀最痛那幾天，美國醫院靠 Exparel。Viatris 才花 16.5 億美元買下它，11 天後台灣 TLC-KY 的 TLC590 在三期正面對打：止痛贏、鴉片也用得少，168 小時仍顯著。"
        }
      ]
    },
    {
      "name": "AI 製藥與新技術",
      "count": 6,
      "articles": [
        {
          "title": "The Semiconductor Moment in AI Drug Discovery",
          "date": "2026-11-06",
          "url": "https://drugnews.com.tw/articles/2026-11-06-anhorn-ai-drug-discovery-semiconductor-moment-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "AI"
          ],
          "summary": "How AI platforms and the discovery flywheel could open new partnership opportunities for AnHorn"
        },
        {
          "title": "AI製藥的半導體時刻",
          "date": "2026-11-06",
          "url": "https://drugnews.com.tw/articles/2026-11-06-anhorn-ai-drug-discovery-semiconductor-moment.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "AI"
          ],
          "summary": "從巨頭入局與正向飛輪到成藥交易　安宏資產與合作的切入點"
        },
        {
          "title": "Anthropic上市想做藥，最後還是賣給藥廠",
          "date": "2026-11-01",
          "url": "https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "Anthropic",
            "AI製藥",
            "IPO",
            "諾和諾德",
            "CDMO"
          ],
          "summary": "Anthropic 10/26 公開 S-1，上半年營收 162.86 億美元，並把濕實驗室、Coefficient Bio 與自有藥物計畫寫進成長故事。它暫不做人體試驗，前十大藥廠九家是客戶；最可能的出路是把候選分子授權給藥廠，而不是自己做到上市。"
        },
        {
          "title": "Anthropic's Drug Lab Will Sell to Pharma",
          "date": "2026-11-01",
          "url": "https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "Anthropic",
            "AI drug discovery",
            "IPO",
            "Novo Nordisk",
            "CDMO"
          ],
          "summary": "Anthropic's S-1 shows $16.29bn in H1 2026 revenue and puts a wet lab, Coefficient Bio and in-house drug programs into its growth story. It is not running human trials, and nine of the top ten drugmakers are customers. Its likeliest path: license candidates to pharma."
        },
        {
          "title": "AZ 的 AI 大單只先付 3%，人體數據才值錢",
          "date": "2026-10-21",
          "url": "https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "AstraZeneca",
            "insitro",
            "AI 新藥",
            "Isomorphic Labs",
            "MASH"
          ],
          "summary": "10 月 15 日，AstraZeneca 和 insitro 簽下最高 15 億美元的 AI 合約，簽約先付只有 4,000 萬。五筆 AI 大單先付都在 1% 到 3%，武田買一支有二期數據的藥，先付 40 億。標靶是門票，人體數據才是籌碼。"
        },
        {
          "title": "AstraZeneca's $1.5B AI Deal Pays 2.7% Up Front",
          "date": "2026-10-21",
          "url": "https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "AstraZeneca",
            "insitro",
            "AI drug discovery",
            "Isomorphic Labs",
            "MASH"
          ],
          "summary": "On Oct 15, AstraZeneca signed insitro to an AI deal worth up to $1.5B, paying $40M at signing. Five AI deals pay 1-3% up front; Takeda paid $4B for a drug with Phase 2 data. Targets are tickets; human data is leverage."
        }
      ]
    },
    {
      "name": "GLP-1 與代謝賽道",
      "count": 3,
      "articles": [
        {
          "title": "RFK Jr. Clears Peptides, Hims Reruns GLP-1 Play",
          "date": "2026-11-04",
          "url": "https://drugnews.com.tw/articles/2026-11-04-hhs-peptide-compounding-bpc157-hims-glp1-playbook-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "peptides",
            "BPC-157",
            "Hims & Hers",
            "compounding",
            "GLP-1"
          ],
          "summary": "HHS will not enforce against pharmacies compounding BPC-157 and five other unapproved peptides. Hims & Hers opened a waitlist the next day, rerunning its compounded-GLP-1 model. In Taiwan, unlicensed imports remain prohibited drugs."
        },
        {
          "title": "Ozempic Face: Galderma's Opportunity",
          "date": "2026-10-26",
          "url": "https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra-en.html",
          "language": "en",
          "category": "商業分析",
          "access": "Business Analysis",
          "tags": [
            "Ozempic face",
            "GLP-1 facial volume loss",
            "Sculptra",
            "Galderma",
            "Caliway CBL-514"
          ],
          "summary": "GLP-1 users are losing facial fat, not collagen, so creams can't fix 'Ozempic face.' In Q2 2026, Galderma's fillers and biostimulators grew 7.6% while AbbVie's Juvéderm fell 6.6%."
        },
        {
          "title": "瘦瘦針臉垮，乳霜補不回，Galderma先贏",
          "date": "2026-10-26",
          "url": "https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "Ozempic臉",
            "瘦瘦針 臉凹",
            "GLP-1 臉部凹陷",
            "舒顏萃 Sculptra",
            "康霈 CBL-514"
          ],
          "summary": "打瘦瘦針瘦了，臉也凹了。L'Oréal 忙著找 GLP-1 用戶測乳霜，但少掉的是皮下脂肪，乳霜擦不到。錢正流向針劑：第二季 Galderma 填充與刺激劑 +7.6%，AbbVie 喬雅登卻衰退 6.6%。"
        }
      ]
    },
    {
      "name": "CMC / 商業化風險",
      "count": 1,
      "articles": [
        {
          "title": "羅氏花4億美元，包下翰森的ADC工廠",
          "date": "2026-10-29",
          "url": "https://drugnews.com.tw/articles/2026-10-29-hansoh-roche-adc-platform-deal.html",
          "language": "zh-Hant",
          "category": "商業分析",
          "access": "商業分析文",
          "tags": [
            "翰森製藥",
            "羅氏 Roche",
            "ADC",
            "中國授權",
            "全球醫藥交易"
          ],
          "summary": "翰森 10/19 與羅氏簽 ADC 合作：首付 4 億美元、頭條逾 155 億美元。羅氏指定靶點、翰森用平台做到 Ia 期，首付比一年前買單顆藥高五倍——羅氏買的是研發產能。"
        }
      ]
    }
  ]
}
